Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus

NCT01023711 | Completed Results

• 1 other identifier: URMC 09-005
• Study Type: interventional
• Target: 107
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to describe the immune response to a novel H1N1 influenza vaccination in healthy adults, and to understand the factors that allow healthy adults to respond to a single dose of vaccine even if they have never previously experience novel H1N1 disease or vaccination.

Conditions

Influenza

Keywords

Influenza

Outcome Measures

Primary Outcomes (1)

• Determination of Immune Response to Vaccination.

  Number of participants with a 4-fold or greater increase in serum HAI antibody from pre- to 28 day post-vaccination

  28 days

Secondary Outcomes (1)

• Assessment of the Reactogenicity Events Post Vaccination.

  7 days

Study Arms (1)

Inactivated H1N1 Vaccine

OTHER

Subject will recieve 0.5 mL IM injection of Inactivated H1N1 vaccine

Biological: Inactivated H1N1 vaccine

Interventions

Inactivated H1N1 vaccine BIOLOGICAL

0.5 ml IM into Deltoid region of arm

Also known as: Influenza A (H1 N1) 2009 Monovalent Vaccine

Inactivated H1N1 Vaccine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18-32 years, or 60 years and older
• No history of Novel H1N1 virus or vaccine
• Female not able to bear children or not pregnant and agrees to practice effective birth control
• Female negative pregnancy test
• Good Health
• Ability to understand and comply with protocol
• Provided Informed Consent

You may not qualify if:

• Previous history of vaccination against novel H1N1 or laboratory documented H1N1 infection
• Previous history of vaccination with A/New Jersey/76 vaccine (for subjects 60 \& older
• History of egg allergy or is allergic to other components of the vaccine
• Women who are pregnant or breastfeeding or intends to get pregnant during the study period between enrollment \& 30 days following vaccination
• Subject is immunosuppressed as the result of underlying illness or treatment with immunosuppressive or cytotoxic drugs or use of chemotherapy/radiation therapy in the preceding 36 months
• Subject has active neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) or a history of any hematological malignancy. "Active" is defined as treatment within the past 5 years.
• Long term (greater than 2 weeks) use of oral or parental steroids, or high- dose inhaled steroids (\>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal \& topical steroids allowed)
• Received immunoglobulin or other blood product within 3 months prior to enrollment in this study
• Subject has received an inactivated vaccine within 2 weeks or a live vaccine within 4 weeks prior to enrollment or plans to receive another vaccine within the next 28 days
• Subject has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses. Those conditions include chronic conditions recognized as risk factors for influenza complications or as contraindicated for live vaccination, including chronic cardiac (exclusive of hypertension) or pulmonary conditions (including asthma), diabetes mellitus, or renal impairment
• Subject has an acute illness or an oral temperature greater then 99.9 F(37.7 C)within 3 days of enrollment or vaccination. Subject who has acute illness that was treated, symptoms resolved are eligible to enroll as long as treatment is complete \& symptoms resolved \> 3 days prior to enrollment.
• Subject is currently participating or plans to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has received an experimental agent within 1 month of enrollment in this study, or intends to donate blood during this period.
• Subject has any condition that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol
• Subject has a diagnosis of schizophrenia, bi-polar disease, or other severe (disabling) chronic psychiatric diagnosis, or are receiving psychiatric drugs. Subjects who are receiving a single anti-depressant drug \& are stable for at least 3 months prior to enrollment without decompensation are allowed enrollment into the study.
• Subject has a history of alcohol or drug abuse in the 5 years of enrollment.

Sponsors & Collaborators

• University of Rochester: lead

Study Sites (1)

Vaccine Research Unit Room 3-5000

Rochester, New York, 14642, United States

Location

MeSH Terms

Conditions

Influenza, Human

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases

Results Point of Contact

• Title: John Treanor, M.D.
• Organization: University of Rochester

john_treanor@urmc.rochester.edu

585-275-5871

Study Officials

• John J. Treanor, M.D.

  University of Rochester

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: December 1, 2009
• First Posted: December 2, 2009
• Study Start: November 1, 2009
• Primary Completion: November 1, 2010
• Study Completion: July 1, 2011
• Last Updated: May 12, 2015
• Results First Posted: May 12, 2015

Record last verified: 2015-04

Locations

US (1)